<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Toxicol</journal-id><journal-id journal-id-type="iso-abbrev">Front Toxicol</journal-id><journal-id journal-id-type="pmc-domain-id">4173</journal-id><journal-id journal-id-type="pmc-domain">ftox</journal-id><journal-id journal-id-type="publisher-id">Frontiers in Toxicology</journal-id><journal-title-group><journal-title>Frontiers in Toxicology</journal-title></journal-title-group><issn pub-type="epub">2673-3080</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9099212</article-id><article-id pub-id-type="pmcid-ver">PMC9099212.1</article-id><article-id pub-id-type="pmcaid">9099212</article-id><article-id pub-id-type="pmcaiid">9099212</article-id><article-id pub-id-type="pmid">35573278</article-id><article-id pub-id-type="doi">10.3389/ftox.2022.894569</article-id><article-id pub-id-type="publisher-id">894569</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Toxicology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Considerations for Improving Metabolism Predictions for <italic toggle="yes">In Vitro</italic> to <italic toggle="yes">In Vivo</italic> Extrapolation</article-title><alt-title alt-title-type="left-running-head">Moreau et al.</alt-title><alt-title alt-title-type="right-running-head">Improving Metabolism Predictions for IVIVE</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Moreau</surname><given-names initials="M">Marjory</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c001" ref-type="corresp">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1755151/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mallick</surname><given-names initials="P">Pankajini</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1755586/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Smeltz</surname><given-names initials="M">Marci</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1757294/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Haider</surname><given-names initials="S">Saad</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nicolas</surname><given-names initials="CI">Chantel I.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pendse</surname><given-names initials="SN">Salil N.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/284385/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Leonard</surname><given-names initials="JA">Jeremy A.</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Linakis</surname><given-names initials="MW">Matthew W.</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1664421/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>McMullen</surname><given-names initials="PD">Patrick D.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1776935/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Clewell</surname><given-names initials="RA">Rebecca A.</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Clewell</surname><given-names initials="HJ">Harvey J.</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1658354/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yoon</surname><given-names initials="M">Miyoung</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1754859/overview"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>ScitoVation, LLC</institution>, <addr-line>Durham</addr-line>, <addr-line>NC</addr-line>, <country>United States</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Oak Ridge Institute for Science and Education</institution>, <addr-line>Oak Ridge</addr-line>, <addr-line>TN</addr-line>, <country>United States</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Ramboll US Corp.</institution>, <addr-line>Research Triangle Park</addr-line>, <addr-line>NC</addr-line>, <country>United States</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>21st Century Tox Consulting</institution>, <addr-line>Chapel Hill</addr-line>, <addr-line>NC</addr-line>, <country>United States</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1172770/overview" ext-link-type="uri">Nynke Kramer</ext-link>, Wageningen University and Research, Netherlands</p></fn><fn fn-type="edited-by"><p>
<bold>Reviewed by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1721553/overview" ext-link-type="uri">Iain Gardner</ext-link>, Certara United Kingdom Limited, United Kingdom</p><p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/12913/overview" ext-link-type="uri">Ursula Gundert-Remy</ext-link>, Charit&#233; Universit&#228;tsmedizin Berlin, Germany</p></fn><corresp id="c001">*Correspondence: Marjory Moreau, <email>mmoreau@scitovation.com</email></corresp><fn fn-type="other"><p>This article was submitted to In Vitro Toxicology, a section of the journal Frontiers in Toxicology</p></fn></author-notes><pub-date pub-type="epub"><day>29</day><month>4</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>4</volume><issue-id pub-id-type="pmc-issue-id">402864</issue-id><elocation-id>894569</elocation-id><history><date date-type="received"><day>11</day><month>3</month><year>2022</year></date><date date-type="accepted"><day>13</day><month>4</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>04</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>14</day><month>05</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2022-06-11 14:16:45.840"><day>11</day><month>06</month><year>2022</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2022 Moreau, Mallick, Smeltz, Haider, Nicolas, Pendse, Leonard, Linakis, McMullen, Clewell, Clewell and Yoon.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Moreau, Mallick, Smeltz, Haider, Nicolas, Pendse, Leonard, Linakis, McMullen, Clewell, Clewell and Yoon</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ftox-04-894569.pdf"/><abstract><p>High-throughput (HT) <italic toggle="yes">in vitro</italic> to <italic toggle="yes">in vivo</italic> extrapolation (IVIVE) is an integral component in new approach method (NAM)-based risk assessment paradigms, for rapidly translating <italic toggle="yes">in vitro</italic> toxicity assay results into the context of <italic toggle="yes">in vivo</italic> exposure. When coupled with rapid exposure predictions, HT-IVIVE supports the use of HT <italic toggle="yes">in vitro</italic> assays for risk-based chemical prioritization. However, the reliability of prioritization based on HT bioactivity data and HT-IVIVE can be limited as the domain of applicability of current HT-IVIVE is generally restricted to intrinsic clearance measured primarily in pharmaceutical compounds. Further, current approaches only consider parent chemical toxicity. These limitations occur because current state-of-the-art HT prediction tools for clearance and metabolite kinetics do not provide reliable data to support HT-IVIVE. This paper discusses current challenges in implementation of IVIVE for prioritization and risk assessment and recommends a path forward for addressing the most pressing needs and expanding the utility of IVIVE.</p></abstract><kwd-group><kwd>IVIVE</kwd><kwd><italic toggle="yes">in vitro</italic></kwd><kwd>metabolism</kwd><kwd>QSAR</kwd><kwd>HT-IVIVE</kwd><kwd>risk assessment</kwd></kwd-group><funding-group><award-group><funding-source id="cn001"><institution-wrap><institution>American Chemistry Council
</institution><institution-id institution-id-type="doi">10.13039/100007824</institution-id></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Widespread implementation of risk assessment strategies based on <italic toggle="yes">in vitro</italic> methods requires fundamental changes in how safety evaluations and decisions are made, along with well-defined frameworks for the use of <italic toggle="yes">in vitro</italic> experiments coupled with high throughput (HT) computational tools (new approach methods; NAMs) to meet the needs of the ever-evolving regulatory, scientific, and legislative landscapes. Rapid progress in development of new <italic toggle="yes">in silico</italic> and <italic toggle="yes">in vitro</italic> methods is facilitating the movement away from animal studies and should help to increase confidence in chemical safety decisions based on new approach methodologies (NAMs). Recent case studies have demonstrated that <italic toggle="yes">in silico</italic> tools, such as the threshold for toxicological concern (TTC), and HT <italic toggle="yes">in vitro</italic> assays coupled with HT <italic toggle="yes">in vitro</italic> to <italic toggle="yes">in vivo</italic> extrapolation (HT-IVIVE) generally provide conservative estimates for chemical points of departure (PoD), and therefore offer a viable alternative to the use of traditional approaches for prioritizing chemicals based on potential risk (<xref rid="B45" ref-type="bibr">Patlewicz et al., 2018</xref>).</p><p>HT-IVIVE, a critical tool for translating <italic toggle="yes">in vitro</italic> bioactivity into estimated human <italic toggle="yes">in vivo</italic> exposures, uses values for parent chemical loss via metabolism, renal clearance, plasma binding, and absorption to predict external exposures that would give rise to steady state parent chemical plasma concentrations equivalent to active concentrations in the <italic toggle="yes">in vitro</italic> test medium (<xref rid="B52" ref-type="bibr">Rotroff et al., 2010</xref>; <xref rid="B67" ref-type="bibr">Wetmore et al., 2013</xref>; <xref rid="B54" ref-type="bibr">Sipes et al., 2017</xref>). To do this, <italic toggle="yes">in vitro</italic> metabolism data is necessary, together with pharmacokinetic (PK) modeling, in a process referred to as reverse dosimetry (<xref rid="B9" ref-type="bibr">Clewell et al., 2008</xref>). While this process is essential to translating <italic toggle="yes">in vitro</italic> bioactivity measurements to human <italic toggle="yes">in vivo</italic> exposures, several limitations in the implementation of HT-IVIVE to the broader chemical Universe exist. Due to challenges with analytical chemistry, cell culture and financial limitations, metabolism data is typically collected in short-term incubations with microsomes or primary hepatocytes with readouts for parent chemical loss. Thus, in the majority of HT uses, IVIVE considers the parent chemical as the only potentially bioactive moiety. Further, expansion of HT-IVIVE to chemicals beyond the 301 chemicals measured in <xref rid="B66" ref-type="bibr">Wetmore et al. (2015)</xref> has been limited by the cost and time required to develop necessary analytical chemistry methods. Here, our main goal was to evaluate approaches for incorporating metabolism information into HT-IVIVE approaches, discuss their domains of applicability and recommend research strategies for rapid improvement of current HT-IVIVE capabilities.</p><sec id="s1-1"><title>Evaluation of Current Tools for Clearance Predictions</title><sec id="s1-1-1"><title>Published <italic toggle="yes">in vitro</italic> Metabolism Data</title><p>For cost and time efficiency, it is common to examine literature data as a source for metabolism characterization. Most published metabolic clearance data are measured using subcellular fractions, such as microsomes and cytosol, or primary cell monoculture systems. These systems are typically derived from the liver of the target species, though clearance from other tissues such as intestine, lung, and kidney may be reported when extrahepatic metabolism is known to be important for a particular chemical. Incubation with subcellular fractions or primary hepatocytes are generally performed over a few hours, as loss of enzyme activity occurs quickly <italic toggle="yes">in vitro</italic> (<xref rid="B42" ref-type="bibr">Nussler et al., 2001</xref>; <xref rid="B68" ref-type="bibr">Wilk-Zasadna et al., 2015</xref>; <xref rid="B8" ref-type="bibr">Cassim et al., 2017</xref>).</p><p>The greatest challenge in using existing literature data for parameterizing IVIVE models resides is the fact that <italic toggle="yes">in vivo</italic> metabolism is an integrated process involving several competing and/or interacting reactions, which may not be completely captured by the more simplified model systems that are typically used. Thus, while microsomal fractions are used often in the published literature, the domain of applicability for these methods is limited to a subset of the chemical Universe that relies on phase I cytochrome-P450-mediated oxidative reactions, carboxylesterases and epoxide hydrolases achieved with traditional microsomal incubations. While phase II metabolism via glucuronide conjugation may also be captured by microsomal preparations, other enzymes, such as the soluble phase II enzymes (sulfotransferases, glutathione s-transferases, etc.,) are neglected (<xref rid="B58" ref-type="bibr">Taylor and Triggle, 2007</xref>; <xref rid="B14" ref-type="bibr">Decker et al., 2009</xref>). While isolated cytosolic fractions may be used to evaluate these processes, this approach is far less common than the use of microsomes. Additionally, since specific cofactors must be added to facilitate some of the cytosolic enzymes, it can be difficult to find published cytosolic enzyme data for all but the most thoroughly studied chemicals. Liver S9 fraction or homogenate can also be used as they contain the major phase I and II enzymes. However their preparation is laborious (<xref rid="B47" ref-type="bibr">Pelkonen et al., 2009</xref>). Human liver slices have the advantage of having a preserved basic hepatic architecture, with an intact cell system and the major phase I and II enzymes. The only drawbacks are the difficulty to obtain the human liver slices and the specialized skills needed (<xref rid="B13" ref-type="bibr">de Graaf et al., 2010</xref>).</p><p>For the reasons described above, freshly isolated primary hepatocytes are regarded as the most relevant experimental system to study both hepatic metabolism and metabolite-mediated effects of chemicals and pharmaceuticals. Primary hepatocytes express most of the proteins found in the human liver, including those involved in metabolism, membrane transport, and receptor-mediated processes (<xref rid="B29" ref-type="bibr">Li et al., 1995</xref>; <xref rid="B60" ref-type="bibr">Vildhede et al., 2015</xref>; <xref rid="B69" ref-type="bibr">Yang et al., 2015</xref>). Primary hepatocytes in suspension are the gold standard for incubation periods up to 4&#160;h but their viability is time limited (<xref rid="B55" ref-type="bibr">Smith et al., 2012</xref>). Plated primary hepatocytes are also the gold standard but for incubation periods longer than 4&#160;h (<xref rid="B55" ref-type="bibr">Smith et al., 2012</xref>; <xref rid="B36" ref-type="bibr">Ma et al., 2017</xref>). However, a major drawback with plated primary hepatocytes is the rapid change in phenotype observed in culture; enzyme activity changes dramatically in the first hours after isolation (for fresh hepatocytes) or thawing (for cryopreserved hepatocytes). In most hepatocytes, the enzymatic activity decreases by approximatively 50% in the first 5&#8211;6&#160;h, with a 95% reduction in enzyme activity within 30&#160;h for most preparations (<xref rid="B42" ref-type="bibr">Nussler et al., 2001</xref>; <xref rid="B8" ref-type="bibr">Cassim et al., 2017</xref>). To overcome the short-life span of these preparations, several techniques have been developed to stabilize hepatic phenotype over longer periods (<xref rid="B61" ref-type="bibr">Vinci et al., 2010a</xref>; <xref rid="B62" ref-type="bibr">Vinci et al., 2010b</xref>; <xref rid="B3" ref-type="bibr">Ballard et al., 2016</xref>). However, these methods have not been routinely used for metabolism studies. Thus, current published metabolism data are subject to the limitations of short-term <italic toggle="yes">in vitro</italic> assays, including an inability to measure clearance of slowly metabolized compounds, which will be discussed in more detail in later sections.</p><p>Another common issue encountered when using literature-derived results for subcellular fractions or isolated hepatocytes is the effect of incubation conditions, such as protein content and substrate concentrations, on estimated intrinsic clearance (CL<sub>int</sub>). Estimates can vary widely for the same compound due to differences in the experimental protocol. To demonstrate this variability, we compared the published human clearance data on the conversion of the well-studied compound, bisphenol A (BPA), to its glucuronide metabolite (<xref rid="T1" ref-type="table">Table 1</xref>). All of these studies used different incubation conditions, and the resulting intrinsic clearance rates differ by more than an order of magnitude. It should be noted that different <italic toggle="yes">in vitro</italic> conditions could lead to different <italic toggle="yes">in vitro</italic> binding, which may be a significant source of variability, particularly depending on how it is (or is not) addressed (<xref rid="B50" ref-type="bibr">Proen&#231;a et al., 2021</xref>).</p><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1</label><caption><p>Metabolism kinetics of BPA found in the literature.</p></caption><table frame="hsides" rules="groups"><thead valign="top"><tr><th align="left" rowspan="1" colspan="1">References</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">V</italic>
<sub>max</sub>
</th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">K</italic>
<sub>M</sub> (&#181;M)</th><th align="center" rowspan="1" colspan="1">CL<sub>int_invitro</sub>
</th><th align="center" rowspan="1" colspan="1">CL<sub>int_invivo</sub> (L/h)<xref rid="Tfn1" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="center" rowspan="1" colspan="1">Metabolic system</th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1">
<xref rid="B24" ref-type="bibr">Kuester and Sipes (2007)</xref>
</td><td align="left" rowspan="1" colspan="1">438&#160;pmol/min/10<sup>6</sup> cells</td><td align="center" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">56&#160;&#956;l/min/10<sup>6</sup> cells</td><td align="char" char="." rowspan="1" colspan="1">590<xref rid="Tfn2" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">Cryopreserved hepatocytes</td></tr><tr><td align="left" rowspan="1" colspan="1">
<xref rid="B17" ref-type="bibr">Elsby et al. (2001)</xref>
</td><td align="left" rowspan="1" colspan="1">5.9&#160;nmol/min/mg protein</td><td align="center" rowspan="1" colspan="1">77.5</td><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">292<xref rid="Tfn3" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">Pooled liver microsomes</td></tr><tr><td align="left" rowspan="1" colspan="1">
<xref rid="B25" ref-type="bibr">Kurebayashi et al. (2010)</xref>
</td><td align="left" rowspan="1" colspan="1">10.6&#160;ml/h/10<sup>6</sup> cells</td><td align="center" rowspan="1" colspan="1">5.3</td><td align="left" rowspan="1" colspan="1">2&#160;ml/h/10<sup>6</sup> cells</td><td align="char" char="." rowspan="1" colspan="1">351<xref rid="Tfn2" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">Cryopreserved hepatocytes</td></tr><tr><td align="left" rowspan="1" colspan="1">Trdan <xref rid="B59" ref-type="bibr">Lu&#353;in et al. (2012)</xref>
</td><td align="left" rowspan="1" colspan="1">8.5&#160;nmol/min/mg protein</td><td align="center" rowspan="1" colspan="1">8.9</td><td align="left" rowspan="1" colspan="1">0.95&#160;ml/min/mg protein</td><td align="char" char="." rowspan="1" colspan="1">3637<xref rid="Tfn3" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">Liver microsomes</td></tr><tr><td align="left" rowspan="1" colspan="1">
<xref rid="B39" ref-type="bibr">Mazur et al. (2010)</xref>
</td><td align="left" rowspan="1" colspan="1">2077&#160;pmol/min/mg protein</td><td align="center" rowspan="1" colspan="1">3.6</td><td align="left" rowspan="1" colspan="1">649&#160;&#956;l/min/mg protein</td><td align="char" char="." rowspan="1" colspan="1">2486<xref rid="Tfn3" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">Liver microsomes</td></tr><tr><td align="left" rowspan="1" colspan="1">
<xref rid="B52" ref-type="bibr">Rotroff et al. (2010)</xref>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">25.04&#160;&#956;l/min/10<sup>6</sup> cells</td><td align="char" char="." rowspan="1" colspan="1">264<xref rid="Tfn2" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">Hepatocytes</td></tr></tbody></table><table-wrap-foot><fn id="Tfn1"><label>a</label><p>Calculated <italic toggle="yes">V</italic>
<sub>max</sub> = maximal velocity of metabolic clearance; <italic toggle="yes">K</italic>
<sub>M</sub>, Michaelis-Menten parameter (half-maximal metabolism concentration)</p></fn><fn id="Tfn2"><label>b</label><p>CL<sub>int_invivo</sub> = CL<sub>int_invitro</sub> &#215; HPGL (hepatocytes per gram liver: 110&#160;million cells/g liver) &#215; Volume liver (1,596&#160;g) &#215; 60&#160;min/h.</p></fn><fn id="Tfn3"><label>c</label><p>CL<sub>int_invivo</sub> = CL<sub>int_invitro</sub> &#215; MPPGL (mg of microsome protein/g liver: 40) &#215; Volume liver (1,596&#160;g) &#215; 60&#160;min/h.</p></fn></table-wrap-foot></table-wrap><p>Thus, in identifying and using data from published studies, care must be taken to evaluate the study conditions and avoid using clearance predictions outside the bounds of the data. For example, studies that report rates of clearance using a single concentration should only be used if the chemical concentration was below the level of enzyme saturation. Another challenge is that studies will often provide results with insufficient detail to reproduce the calculations. These types of difficulties are quite common when looking at <italic toggle="yes">in vitro</italic> metabolic literature and can pose a significant challenge when using these results to perform HT-IVIVE.</p></sec><sec id="s1-1-2"><title>Available <italic toggle="yes">In Silico</italic> Metabolism Models</title><p>A large number of <italic toggle="yes">in silico</italic> models have been developed over the years for predicting metabolism based on QSARs (<xref rid="B15" ref-type="bibr">Ekins and Obach 2000</xref>; <xref rid="B27" ref-type="bibr">Lee et al., 2007</xref>; <xref rid="B30" ref-type="bibr">Li et al., 2009</xref>; <xref rid="B34" ref-type="bibr">Lombardo et al., 2014</xref>; <xref rid="B53" ref-type="bibr">Sarigiannis et al., 2017</xref>; <xref rid="B54" ref-type="bibr">Sipes et al., 2017</xref>). These models typically take advantage of the large (but often proprietary) data sets developed during drug candidate screening, and are often focused on the development of classification models (e.g., metabolized vs. not metabolized), enzyme substrate identification (<xref rid="B21" ref-type="bibr">Holmer et al., 2021</xref>), metabolite identification (<xref rid="B12" ref-type="bibr">de Bruyn Kops et al., 2021</xref>), or prediction of metabolism by a particular class of enzymes (<xref rid="B40" ref-type="bibr">Mazzolori et al., 2019</xref>; <xref rid="B57" ref-type="bibr">Sweeney and Sterner 2022</xref>), rather than quantitative prediction of total clearance. Models developed primarily from pharmaceutical compound data share a common deficiency from the viewpoint of their application to chemicals other than drugs, in that the characteristics that make a compound suitable for use as a drug are often quite different from the characteristics of compounds of environmental and occupational interest (<xref rid="B28" ref-type="bibr">Leanard 2019</xref>). The properties considered important for a potential oral drug are those characteristics that will provide high bioavailability (as described in <xref rid="B31" ref-type="bibr">Lipinski et al., 2016</xref>) as follows:<list list-type="simple"><list-item><p>&#8226; nonvolatile</p></list-item><list-item><p>&#8226; water soluble</p></list-item><list-item><p>&#8226; moderate to high permeability</p></list-item><list-item><p>&#8226; low lipophilicity</p></list-item><list-item><p>&#8226; not highly ionized at pH = 7.4</p></list-item><list-item><p>&#8226; low to moderate clearance</p></list-item><list-item><p>&#8226; good stability in plasma</p></list-item></list>
</p><p>Environmental chemicals, however, are not subject to these limitations as they are designed for many purposes other than efficient biological uptake. Moreover, while there are more than 50 CYP450 enzymes, a small subset (1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4/5) metabolize 90% of drugs, and important CYPs for environmental and occupational inhalation exposures (<italic toggle="yes">e.g.</italic>, 1A1, 2E1, and 2F1) are seldom considered in drug development. Thus, the utility of models based on drug data for predicting metabolic transformations for environmental chemicals is uncertain.</p><p>We compared human <italic toggle="yes">in vivo</italic> CL<sub>int</sub> estimates from one of the commonly used in silico models, ADMET predictor (Simulations Plus, ver. 7.1), which is trained using data from pharmaceuticals, for 301 ToxCast chemicals with CL<sub>int</sub> estimates derived from <italic toggle="yes">in vitro</italic> hepatocyte metabolism studies (<xref rid="B66" ref-type="bibr">Wetmore et al., 2015</xref>) as published in <xref rid="B54" ref-type="bibr">Sipes et al. (2017)</xref>. The relationship between experimentally measured and predicted CL<sub>int</sub> values is shown in <xref rid="F1" ref-type="fig">Figure 1</xref>. Overall, the <italic toggle="yes">in vitro</italic> experimental and predicted values are not well-correlated (<italic toggle="yes">r</italic>
<sup>2</sup> = 0.00014), a finding that is at least partially due to the fact that the training set for the predictive tool was developed based on data from pharmaceuticals, while the chemicals from ToxCast likely have a much broader range of physicochemical properties. Additionally, inadequacies of the <italic toggle="yes">in vitro</italic> assays to which the predictions are compared may also play a role (see next section).</p><fig position="float" id="F1" orientation="portrait"><label>FIGURE 1</label><caption><p>Comparison of measured (<xref rid="B66" ref-type="bibr">Wetmore et al., 2015</xref>) and predicted (ADMET predictor, ver7.1, SimulationsPlus) intrinsic clearance (CL<sub>int</sub>) for a subset of ToxCast chemicals. The red line represents the linear regression with <italic toggle="yes">R</italic>
<sup>2</sup> = 0.00014. The solid yellow line represents equivalence between predicted and measured values (y = x) and the dashed yellow lines represent a 10-fold divergence between predicted and measured values (y = 10 &#215; x; y = x/10).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ftox-04-894569-g001.jpg"/></fig><p>Since many of the tools used for IVIVE analysis were originally developed for pharmaceuticals, their performance against the more diverse set of chemicals encountered in the environment needs to be properly evaluated (<xref rid="B5" ref-type="bibr">Bell et al., 2017</xref>). To investigate the similarity in the physical-chemical properties across pharmaceutical and environmental chemicals, we used the chemical descriptor information from the Collaborative Estrogen Receptor Activity Prediction Project (CERAPP) database (<xref rid="B38" ref-type="bibr">Mansouri et al., 2016</xref>) to visualize the relationship between the chemical space of pharmaceutical and environmental chemicals (<xref rid="F2" ref-type="fig">Figure 2</xref>). Model descriptors were physical-chemical properties from OPERA, as described in <xref rid="B38" ref-type="bibr">Mansouri et al. (2016)</xref>: vapor pressure (logVP), water solubility (logWS), and lipophilicity (logP). <xref rid="F2" ref-type="fig">Figure 2</xref> demonstrates that pharmaceuticals only represent a subset of the chemical space that is associated, as expected, with low volatility, low lipophilicity and high water solubility.</p><fig position="float" id="F2" orientation="portrait"><label>FIGURE 2</label><caption><p>Scatter plot of the physicochemical properties of environmental chemicals (gold dots) and pharmaceuticals (blue dots) in the CERAPP database. The axes represent vapor pressure (log VP), water solubility (log WS) and lipophilicity (log P). Two different views are shown to illustrate the properties of the environmental chemicals, dioctyl phthalate (left) and PFOSA (right).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ftox-04-894569-g002.jpg"/></fig><p>We further evaluated the chemical space of the 45,000 chemicals in the CERAPP database using principal component analysis (PCA), which is useful for determining descriptors that explain variance (<xref rid="F3" ref-type="fig">Figure 3</xref>). Random Forest analysis was utilized for predicting three exposure proximity classes: near-field (NF), far-field (FF), and pharmaceutical (Rx), after which a principal component analysis was employed using the highest performing decision algorithm. A classification accuracy of 79% was achieved when simultaneously utilizing two descriptor sets: 1) CERAPP physicochemical property with Lapinski descriptors and 2) structural signatures in the form of DSSTox Toxprint chemotypes (<xref rid="B69" ref-type="bibr">Yang et al., 2015</xref>). The most important descriptors identified by the analysis were molecular weight and polar surface area, both of which had an importance of greater than 0.9 for the first and second components, respectively, while all other components were less than 0.3. The analysis also indicated that molecule flexibility and lipophilicity were the major factors distinguishing the pharmaceutical and environmental chemical spaces, with drug-like compounds being confined in a narrower space than environmental chemicals. Many pharmaceutical compounds contain rigid ring-type structures that limit their flexibility. This helps enhance their affinity for the target enzyme by limiting the entropic price of binding. Log <italic toggle="yes">p</italic> values for pharmaceuticals tend to be moderate: high enough to allow passage through cell membranes, while still low enough to avoid issues with bioavailability and solubility (<xref rid="B31" ref-type="bibr">Lipinski 2016</xref>). As environmental chemicals are not designed to meet the same criteria, they do not have these features constrained. To assess the significance of this discrepancy, we calculated the Frobenius distance (Euclidian norm of (D1-D2)) between pairs of distributions. The resulting distances (Rx-NF = 2.35, Rx-FF = 2.58, NF/FF = 0.48) support the conclusion that the Rx distribution can be seen as distinctly different from the other two, indicating that validation of an assay with pharmaceuticals may not adequately ensure the usefulness of the assay for environmental chemicals.</p><fig position="float" id="F3" orientation="portrait"><label>FIGURE 3</label><caption><p>Principal component analysis. All chemicals (CERAPP, gray), environmental chemicals from ToxCast (red), and top prescribed drugs (blue). The blue bubble surrounds the Top Pharmaceutical compounds that are one standard deviation away from the mean. The red bubble surrounds the ToxCast and Environmental compounds that are one standard deviation away from the mean.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ftox-04-894569-g003.jpg"/></fig><p>A number of recent efforts have attempted to address the insufficiency of pharmaceutical data for training quantitative structure activity relationship (QSAR) prediction of CL<sub>int</sub> for environmental chemicals by including available data on non-pharmaceuticals, but with limited success (<xref rid="B49" ref-type="bibr">Pradeep et al., 2020</xref>; <xref rid="B11" ref-type="bibr">Dawson et al., 2021a,b</xref>; <xref rid="B37" ref-type="bibr">Mansouri et al., 2021</xref>). Three models, all freely available (including OPERA, which has a downloadable graphic user interface) are described herein. <xref rid="B49" ref-type="bibr">Pradeep et al. (2020)</xref> used a combination of read-across and QSAR to classify 524 pharmaceuticals, food-use chemicals, pesticides, and industrial chemicals into low, medium, and high CL<sub>int</sub> groups. They then used a series of machine learning methods with &#8805; 79 descriptors to develop predictive models for CL<sub>int</sub>, based on the &#8220;medium CL<sub>int</sub>&#8221; chemicals (n = 337). Unfortunately, the fit to the observed data was still fairly poor (test set <italic toggle="yes">r</italic>
<sup>
<italic toggle="yes">2</italic>
</sup> = 0.14), and the model was not correlated to CL<sub>int</sub> predictions from the ADMET software (<italic toggle="yes">r</italic>
<sup>
<italic toggle="yes">2</italic>
</sup> = 0.17). Poor model performance was attributed to uncertainty and variability in the underlying <italic toggle="yes">in vitro</italic> data, as well as the possibility that important chemical descriptors had yet to be identified. <xref rid="B37" ref-type="bibr">Mansouri et al. (2021)</xref> developed a similar capability in the OPERA QSAR app (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ntp.niehs.nih.gov/whatwestudy/niceatm/comptox/ct-opera/opera.html" ext-link-type="uri">https://ntp.niehs.nih.gov/whatwestudy/niceatm/comptox/ct-opera/opera.html</ext-link>). OPERA has a chemical domain of 1,056 non-specific chemicals and utilizes QSAR, classification (cleared vs. non-cleared), and then regression on cleared chemicals to estimate CL<sub>int</sub>. Ultimately, <xref rid="B37" ref-type="bibr">Mansouri et al. (2021)</xref> noted a bimodal distribution of estimated values for CL<sub>int</sub> (centered around &#8764;10<sup>&#8722;6.5</sup> and &#8764;10<sup>1.5</sup>l/hr). The <italic toggle="yes">r</italic>
<sup>2</sup> value for this model was 0.40, which still demonstrates a fair amount of room for improvement, but is much improved over the previous models. <xref rid="B11" ref-type="bibr">Dawson et al. (2021)</xref> built a QSAR model with 40 descriptors using both pharmaceutical and non-pharmaceutical chemicals pulled from ToxCast and ChEMBL databases. Chemicals were classified into very slow, slow, and fast/very fast metabolism, and random forest regression was performed to provide quantitative estimates of CL<sub>int</sub>. The overall average accuracy for the full training set was 58.7% in the training set; however, after filtering to ensure that chemicals were within the applicability domain, the accuracy when applied to ToxCast chemicals was 70.4%. Predictions were poor in the &#8220;very slow&#8221; category, but this was likely due to a severe under-representation of &#8220;slow&#8221; chemicals in the data (8% of the test set). The overall <italic toggle="yes">r</italic>
<sup>2</sup> of the observed vs. predicted random forest regression was 0.52, which indicates some utility for application in early prioritization. Overall, these efforts demonstrate the importance of using relevant data model training and highlight the need for additional CL<sub>int</sub> data collection in the environmental chemical space. The lack of human <italic toggle="yes">in vivo</italic> metabolism data for chemicals that are not pharmaceuticals is a limiting factor in determining the domain of applicability for <italic toggle="yes">in vitro</italic> systems. To address this deficiency, it will be necessary to conduct parallel evaluations in human and rodent tissues to extend the available <italic toggle="yes">in vivo</italic> data.</p></sec></sec><sec id="s1-2"><title>Recommendations for Improving Intrinsic Clearance Predictions</title><sec id="s1-2-1"><title>Using Improved <italic toggle="yes">in vitro</italic> Systems to Collect Data to Support Expansion of Current <italic toggle="yes">in Silico</italic> Models</title><p>Two major areas for future development that were identified from our analysis of current HT-IVIVE capabilities were 1) improved <italic toggle="yes">in vitro</italic> models that allow for <italic toggle="yes">in vivo</italic> -like metabolite profiles over longer periods of time and 2) expanded domain of applicability of clearance prediction models by collecting data from the environmental chemical space. In particular, the prediction of slowly cleared environmental compounds is hindered due to the lack of experimental data. On the basis of a purely practical consideration, it is not possible to determine CL<sub>int</sub> with confidence if rates of metabolism are significantly less that the life-span/duration of metabolic competence of <italic toggle="yes">in vitro</italic> hepatocytes or metabolism assay preparations. Thus, the limitations of enzyme viability in current <italic toggle="yes">in vitro</italic> models is a clear technological gap that must be addressed if predictive models are to be developed for the broader chemical Universe.</p><p>The short-lived nature of most existing <italic toggle="yes">in vitro</italic> models, including the hepatocyte assay used for several HT-IVIVE studies (<xref rid="B52" ref-type="bibr">Rotroff et al., 2010</xref>; <xref rid="B66" ref-type="bibr">Wetmore et al., 2015</xref>), limits their utility for the broader Universe of compounds. Recent developments in 3D and dynamic tissue cultures, <italic toggle="yes">e.g.</italic>, bioreactors, have shown promise for improving estimates of both chemical metabolism and toxicological response (<xref rid="B26" ref-type="bibr">LeCluyse et al., 2012</xref>). For example, <xref rid="B48" ref-type="bibr">Phillips (2018)</xref> developed a 3D primary human hepatocyte cell culture system using alginate hydrogel beads with extended viability and metabolic competence that can be used for long-term primary human hepatocyte culture model with slowly metabolized chemicals. Hepatocytes are viable for more than 4 weeks in this system. Increasing the length of time that hepatocytes could be exposed to chemicals would contribute to addressing the major shortcoming of currently available <italic toggle="yes">in vitro</italic> metabolic clearance determination tools in accurately measuring slow clearance. These longer-lived <italic toggle="yes">in vitro</italic> metabolism tools would also be useful in improving coverage of Phase II metabolic processes and other clearance pathways. As an example, we measured the expression of several Phase I and Phase II metabolism genes in primary hepatocytes cultured in a 3D alginate bead system (<xref rid="B48" ref-type="bibr">Phillips et al., 2018</xref>). As opposed to standard suspension cultures that lose most of their RNA expression in the first day and lose viability in less than 1&#160;week (<xref rid="B26" ref-type="bibr">LeCluyse et al., 2012</xref>), the hepatocytes in this 3D model showed increased expression of most of the measured genes after 4 weeks in culture (<xref rid="F4" ref-type="fig">Figure 4</xref>). Such systems also hold tremendous promise for measuring low abundance or slowly formed metabolites. <xref rid="B6" ref-type="bibr">Bernasconi et al. (2019)</xref> showed in their study that cryopreserved PHH and cryopreserved HepaRG cells are reliable and relevant <italic toggle="yes">in vitro</italic> methods for the assessment of human CYP enzyme induction. HepaRG cell lines are metabolic competent &#8220;hepatocyte-like but they only represent one donor (<xref rid="B5" ref-type="bibr">Bell et al., 2017</xref>). Organoids based on primary hepatic material are also systems that have a close resemblance to <italic toggle="yes">in vivo</italic> physiological situation but there is limited information on their performance (<xref rid="B18" ref-type="bibr">Gough et al., 2021</xref>).</p><fig position="float" id="F4" orientation="portrait"><label>FIGURE 4</label><caption><p>Expression of Phase I and II metabolism genes in freshly plated rat hepatocytes (left) or rat hepatocytes cultured for 28&#160;days in alginate beads. Reproduced from <xref rid="B48" ref-type="bibr">Phillips et al., 2018</xref>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ftox-04-894569-g004.jpg"/></fig><p>Collection of metabolism data in these improved models is nonetheless hindered by the lack of resources for generation of <italic toggle="yes">in vitro</italic> clearance data, the high cost of analytical chemistry, and the low-throughput nature of existing assays. However, we propose that the domain of applicability of current <italic toggle="yes">in silico</italic> metabolism models could be substantially improved while minimizing costs, by strategically selecting a finite set of chemicals that could be used to re-train/update current QSAR models of metabolism. Using computational approaches for defining chemical space, such as those demonstrated in the included chemical space analyses, it is possible to select specific chemicals for testing that target chemical domains of interest. Further, using non-targeted analytical chemistry techniques, we may be able to expand the throughput for metabolism studies (<xref rid="B56" ref-type="bibr">Sobus et al., 2018</xref>).</p></sec></sec><sec id="s1-3"><title>
<italic toggle="yes">In Vitro</italic> to <italic toggle="yes">In Vivo</italic> Extrapolation in a Risk Assessment Context</title><p>HT-IVIVE estimates of human equivalent dose using only parent chemical clearance have been successfully used to support prioritization or screening-level risk evaluations from HT <italic toggle="yes">in vitro</italic> bioactivity data (<xref rid="B52" ref-type="bibr">Rotroff et al., 2010</xref>; <xref rid="B71" ref-type="bibr">Yoon et al., 2012</xref>; <xref rid="B63" ref-type="bibr">Wetmore et al., 2013</xref>; <xref rid="B65" ref-type="bibr">Wetmore et al., 2015</xref>; <xref rid="B54" ref-type="bibr">Sipes et al., 2017</xref>; <xref rid="B7" ref-type="bibr">Casey et al., 2018</xref>; <xref rid="B64" ref-type="bibr">Wambaugh et al., 2018</xref>). However, when used with data from biologically relevant fit-for-purpose assays (<xref rid="B10" ref-type="bibr">Clewell et al., 2016</xref>; <xref rid="B20" ref-type="bibr">Hartman et al., 2018</xref>; <xref rid="B4" ref-type="bibr">Beames et al., 2020</xref>) to derive quantitative estimates of risk, more sophisticated IVIVE models (quantitative-IVIVE; Q-IVIVE) that account for issues such as slow clearance, active transport, extra-hepatic metabolism, and metabolic bioactivation are likely to be necessary (<xref rid="B71" ref-type="bibr">Yoon et al., 2012</xref>; <xref rid="B72" ref-type="bibr">2013</xref>; <xref rid="B70" ref-type="bibr">2016</xref>).</p><p>In a tiered approach to NAM-based risk assessment as described in <xref rid="B1" ref-type="bibr">Andersen et al. (2019)</xref>, rapid computational methods that allow for increased uncertainty may be used to make rapid decisions on chemical prioritization (Level 1), and HT or organotypic <italic toggle="yes">in vitro</italic> assays may be used to make more quantitative assessments (Level 2&#8211;4). The progression between bioactivity linked risk-based evaluations at different tiers is governed by decision context and the degree of confidence required for the decision. For example, if HT methods can determine that human effect levels predicted using computational methods or <italic toggle="yes">in vitro</italic> points of departure are sufficiently large relative to likely human exposure (<italic toggle="yes">i.e.</italic>, the margin of exposure, MOE), a larger degree of uncertainty in the metabolic characterization may be tolerated in decision-making. Conversely, if an early-tier assessment predicts a small margin of exposure with higher uncertainty, successive tiered testing can be used to refine the risk estimate and gain confidence in NAM-based decisions.</p><p>In this schema, HT-IVIVE supported by <italic toggle="yes">in silico</italic> predictions of parent chemical clearance would support rapid prioritization and data collection in more organotypic metabolism models would support higher tier, quantitative assessments. However, as the domain of applicability of current data and predictive models are heavily biased toward the pharmaceutical chemical space, current efforts suggest that even as a first pass, CL<sub>int</sub> predictions are in need of improvement. This situation becomes even more pressing when considering the lack of consideration of metabolite bioactivity.</p></sec><sec id="s1-4"><title>Considering Metabolite Exposure With <italic toggle="yes">In Vitro</italic> to <italic toggle="yes">In Vivo</italic> Extrapolation</title><p>It is important to make risk-based decisions based on the exposure to the active form of the chemical, whether the decisions relate to prioritization or some higher tier risk assessment. In practice, it is not a simple process, because both the tools for assessing <italic toggle="yes">in vitro</italic> bioactivity assays and for measuring <italic toggle="yes">in vitro</italic> metabolism assays may lack the full complement of enzymatic pathways required to activate a test compound and would likely misrepresent the <italic toggle="yes">in vivo</italic> phenotype. As described in <xref rid="F5" ref-type="fig">Figure 5</xref>, when both parent and metabolites are active, the results expected from <italic toggle="yes">in vitro</italic> assays would be true positives. However, when the parent compound is active and the metabolite inactive, the relevance of the results would depend on the similarity of clearance <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo.</italic> If the compound is cleared quickly <italic toggle="yes">in vivo</italic>, spurious effects by the parent might be observed in a cell culture system that lacks the appropriate metabolic capability. In contrast, when the parent compound is inactive and the metabolite is active, the results from <italic toggle="yes">in vitro</italic> screens that lack the appropriate metabolic capability could be false negatives. For example, the phthalate esters (diethylhexyl phthalate, di-n-butyl phthalate) are antiandrogenic <italic toggle="yes">in vivo</italic> due to hydrolysis to the monoester metabolites. <italic toggle="yes">In vitro</italic> , the monoester metabolites inhibit testosterone, but parent chemicals do not (<xref rid="B2" ref-type="bibr">Balbuena et al., 2013</xref>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://comptox.epa.gov/dashboard/chemical/invitrodb/DTXSID2025680" ext-link-type="uri">https://comptox.epa.gov/dashboard/chemical/invitrodb/DTXSID2025680</ext-link>). In this case, a false negative could be produced if the active metabolites were not identified by QSAR of <italic toggle="yes">in vitro</italic> metabolism studies that included esterase activity. Current <italic toggle="yes">in vitro</italic> bioactivity assays rarely consider metabolism, and when they do, the assay conditions are unlikely to mimic <italic toggle="yes">in vivo</italic> metabolite profiles. For example, the most common approach to including metabolism is the addition of S9 fractions from rat hepatocytes, often following induction of specific Phase I pathways using chemicals such as Arochlor 1254 or phenobarbital (<xref rid="B16" ref-type="bibr">Elliott et al., 1992</xref>; <xref rid="B43" ref-type="bibr">Ooka et al., 2020</xref>.). Recombinant expressed enzymes can also be applied to obtain information on metabolism, including the contribution of a single metabolic enzyme or a combination of isozymes to the biotransformation of the chemical, and the identification of potential metabolites (<xref rid="B19" ref-type="bibr">Hariparsad et al., 2006</xref>). The results from the expressed system can also support screening for toxicity of the metabolites (<xref rid="B19" ref-type="bibr">Hariparsad et al., 2006</xref>). From the QIVIVE point of view, another advantage of recombinant systems is the capability of providing human variability information when combined with enzyme abundance data (<xref rid="B32" ref-type="bibr">Lipscomb et al., 2003</xref>; <xref rid="B51" ref-type="bibr">Punt et al., 2010</xref>).</p><fig position="float" id="F5" orientation="portrait"><label>FIGURE 5</label><caption><p>Relevance of <italic toggle="yes">in vitro</italic> assays that lack metabolism to the potential bioactivity of chemicals. Note that the top row (denoted *), will return a true positive but for the wrong reason (because the metabolite is the entity of concern <italic toggle="yes">in vivo</italic>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ftox-04-894569-g005.jpg"/></fig><p>While identifying every single metabolite is likely not feasible for any given test compound or decision context, some understanding of the potential for production of a reactive metabolite and the rate of clearance of major metabolites that raise structural alerts for toxicity is crucial for any NAM-based risk assessment strategy. Hence, some combination of <italic toggle="yes">in silico</italic> tools and <italic toggle="yes">in vitro</italic> assays will be essential to inform the number of potential toxic metabolites, especially at early stages that are intended to facilitate prioritization.</p><p>At this time, no single method for metabolite prediction would be sufficient for assessing metabolite formation. Coupling predictive tools with read-across from literature reviews should aid in identifying the mostly likely metabolites to be formed. As a result, metabolites found to be common across all three sources of information&#8212;literature review, metabolite prediction software and direct <italic toggle="yes">in vitro</italic> identification - would be the most likely candidates for follow-up testing. To identify if metabolism plays a major role in response, the most frequently identified metabolites could be tested. For example, compounds with characterized activity in HT screening efforts (<italic toggle="yes">e.g.</italic>, Tox21, ToxCast), having structural flags for genotoxicity, or that are metabolites expected to be formed might be prioritized for testing. Criteria for inclusion of predicted metabolites for further testing would certainly vary according the decision context. Additionally, if a metabolite had structural characteristics that indicate that it could be more persistent or bioaccumulative than the parent compound, this could also signal the need for follow-up testing.</p><p>However, collection of literature data would likely prove to be the best option only for those few compounds that that have been extensively studied. An alternative to looking through various literature data for poorly characterized compounds would be to develop a more efficient experimental strategy for metabolite identification. A rapid metabolite identification approach based on computer-aided spectrum analysis has the potential to significantly increase throughput and confidence in incorporating metabolites in risk-based decision makings (<xref rid="B73" ref-type="bibr">Zamora et al., 2013</xref>).</p></sec></sec><sec sec-type="conclusion" id="s2"><title>Conclusion</title><p>Significant progress has been made internationally in redefining the paradigm of toxicology testing to support reducing the use of animals and enhancing human risk assessment through the implementation of more human relevant <italic toggle="yes">in vitro</italic>-only strategies. Considerable progress has also been made in developing and applying screening approaches that integrate HT methods with tiered-testing strategies to support a weight-of-evidence approach to chemical safety decision making. HT-IVIVE is an important tool that utilizes <italic toggle="yes">in vitro</italic> experimental data to predict equivalent dose levels <italic toggle="yes">in vivo</italic> via dosimetry. However, there remain significant gaps in both <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in silico</italic> tools related to metabolism that need to be addressed to improve the efficiency and confidence in HT-IVIVE. To address these gaps, the <italic toggle="yes">in vitro</italic> metabolism field requires significant improvements in the rapid identification of likely metabolites, characterization of metabolite formation and clearance processes, and estimation of metabolite kinetics. This task will require a collaborative effort across <italic toggle="yes">in silico</italic>, <italic toggle="yes">in vitro</italic> and analytical chemistry platforms.</p></sec></body><back><ack><p>The authors also thank Martin B. Phillips for his helpful advice and discussion.</p></ack><sec id="s3"><title>Author Contributions</title><p>MM, PM, CN, PM, RC, HC and MY contributed to conception and design of the study. MS, CN, SP, and JL conducted the analyses. MM and MY wrote the first draft of the manuscript. ML, PM, RC, HC and MY wrote sections of the manuscript. All authors contributed to manuscript revision, read, and approved the submitted version.</p></sec><sec id="s4"><title>Funding</title><p>Funding for the research, which was performed at ScitoVation, was provided by the American Chemistry Council&#8217;s Long-Range Research Initiative. (ACC-LRI).</p></sec><sec sec-type="COI-statement" id="s5"><title>Conflict of Interest</title><p>Authors MM, PM, MS, SH, CN, SP, PM and MY were employed by the company ScitoVation, LLC, author RC was employed by the company. 21st Century Tox Consulting and authors ML and HC were employed by the company Ramboll US Corp.</p><p>The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s6"><title>Publisher&#8217;s Note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andersen</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>McMullen</surname><given-names>P. D.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>M. B.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pendse</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Clewell</surname><given-names>H. J.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Developing Context Appropriate Toxicity Testing Approaches Using New Alternative Methods (NAMs)</article-title>. <source>Altex</source><volume>36</volume> (<issue>4</issue>), <fpage>523</fpage>&#8211;<lpage>534</lpage>. <pub-id pub-id-type="doi">10.14573/altex.1906261</pub-id><pub-id pub-id-type="pmid">31664457</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balbuena</surname><given-names>P.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>J.</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Clewell</surname><given-names>H. J.</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Clewell</surname><given-names>R. A.</given-names></name></person-group> (<year>2013</year>). <article-title>Evaluation of a Predictive <italic toggle="yes">In Vitro</italic> Leydig Cell Assay for Anti-androgenicity of Phthalate Esters in the Rat</article-title>. <source>Toxicol. Vitro</source><volume>27</volume>, <fpage>1711</fpage>&#8211;<lpage>1718</lpage>. <pub-id pub-id-type="doi">10.1016/j.tiv.2013.03.015</pub-id><pub-id pub-id-type="pmid">23578968</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ballard</surname><given-names>T. E.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Moen</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Krzyzewski</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ukairo</surname><given-names>O.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Application of a Micropatterned Cocultured Hepatocyte System to Predict Preclinical and Human-specific Drug Metabolism</article-title>. <source>Drug Metab. Disposition</source><volume>44</volume>, <fpage>172</fpage>&#8211;<lpage>179</lpage>. <pub-id pub-id-type="doi">10.1124/dmd.115.066688</pub-id><pub-id pub-id-type="pmid">26608083</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beames</surname><given-names>T.</given-names></name><name name-style="western"><surname>Moreau</surname><given-names>M.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Mansouri</surname><given-names>K.</given-names></name><name name-style="western"><surname>Haider</surname><given-names>S.</given-names></name><name name-style="western"><surname>Smeltz</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The Role of Fit-For-Purpose Assays within Tiered Testing Approaches: A Case Study Evaluating Prioritized Estrogen-Active Compounds in an <italic toggle="yes">In Vitro</italic> Human Uterotrophic Assay</article-title>. <source>Toxicol. Appl. Pharmacol.</source><volume>387</volume>, <fpage>114774</fpage>. <pub-id pub-id-type="doi">10.1016/j.taap.2019.114774</pub-id><pub-id pub-id-type="pmid">31783037</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bell</surname><given-names>C. C.</given-names></name><name name-style="western"><surname>Lauschke</surname><given-names>V. M.</given-names></name><name name-style="western"><surname>Vorrink</surname><given-names>S. U.</given-names></name><name name-style="western"><surname>Palmgren</surname><given-names>H.</given-names></name><name name-style="western"><surname>Duffin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Andersson</surname><given-names>T. B.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Transcriptional, Functional, and Mechanistic Comparisons of Stem Cell-Derived Hepatocytes, HepaRG Cells, and Three-Dimensional Human Hepatocyte Spheroids as Predictive <italic toggle="yes">In Vitro</italic> Systems for Drug-Induced Liver Injury</article-title>. <source>Drug Metab. Dispos</source><volume>45</volume>, <fpage>419</fpage>&#8211;<lpage>429</lpage>. <pub-id pub-id-type="doi">10.1124/dmd.116.074369</pub-id><pub-id pub-id-type="pmid">28137721</pub-id><pub-id pub-id-type="pmcid">PMC5363699</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernasconi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pelkonen</surname><given-names>O.</given-names></name><name name-style="western"><surname>Andersson</surname><given-names>T. B.</given-names></name><name name-style="western"><surname>Strickland</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wilk-Zasadna</surname><given-names>I.</given-names></name><name name-style="western"><surname>Asturiol</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Validation of <italic toggle="yes">In Vitro</italic> Methods for Human Cytochrome P450 Enzyme Induction: Outcome of a Multi-Laboratory Study</article-title>. <source>Toxicol. Vitro</source><volume>60</volume>, <fpage>212</fpage>&#8211;<lpage>228</lpage>. <pub-id pub-id-type="doi">10.1016/j.tiv.2019.05.019</pub-id><pub-id pub-id-type="pmcid">PMC6718736</pub-id><pub-id pub-id-type="pmid">31158489</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Casey</surname><given-names>W. M.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>D. G.</given-names></name><name name-style="western"><surname>Ceger</surname><given-names>P. C.</given-names></name><name name-style="western"><surname>Choksi</surname><given-names>N. Y.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>J. H.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Evaluation and Optimization of Pharmacokinetic Models for <italic toggle="yes">In Vitro</italic> to <italic toggle="yes">In Vivo</italic> Extrapolation of Estrogenic Activity for Environmental Chemicals</article-title>. <source>Environ. Health Perspect.</source><volume>126</volume>, <fpage>97001</fpage>. <pub-id pub-id-type="doi">10.1289/EHP1655</pub-id><pub-id pub-id-type="pmid">30192161</pub-id><pub-id pub-id-type="pmcid">PMC6375436</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cassim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Raymond</surname><given-names>V.-A.</given-names></name><name name-style="western"><surname>Lapierre</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bilodeau</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>From <italic toggle="yes">In Vivo</italic> to <italic toggle="yes">In Vitro</italic>: Major Metabolic Alterations Take Place in Hepatocytes during and Following Isolation</article-title>. <source>PLoS One</source><volume>12</volume>, <fpage>e0190366</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0190366</pub-id><pub-id pub-id-type="pmid">29284039</pub-id><pub-id pub-id-type="pmcid">PMC5746264</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clewell</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y. M.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>M. E.</given-names></name></person-group> (<year>2008</year>). <article-title>Quantitative Interpretation of Human Biomonitoring Data</article-title>. <source>Toxicol. Appl. Pharmacol.</source><volume>231</volume> (<issue>1</issue>), <fpage>122</fpage>&#8211;<lpage>133</lpage>. <pub-id pub-id-type="doi">10.1016/j.taap.2008.04.021</pub-id><pub-id pub-id-type="pmid">18589468</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clewell</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>McMullen</surname><given-names>P. D.</given-names></name><name name-style="western"><surname>Adeleye</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Carmichael</surname><given-names>P. L.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>M. E.</given-names></name></person-group> (<year>2016</year>). <article-title>Pathway Based Toxicology and Fit-For-Purpose Assays</article-title>. <source>Adv. Exp. Med. Biol.</source><volume>856</volume>, <fpage>205</fpage>&#8211;<lpage>230</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-319-33826-2_8</pub-id><pub-id pub-id-type="pmid">27671724</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dawson</surname><given-names>D. E.</given-names></name><name name-style="western"><surname>Ingle</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Nichols</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Wambaugh</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Tornero-Velez</surname><given-names>R.</given-names></name></person-group> (<year>2021</year>). <article-title>Designing QSARs for Parameters of High-Throughput Toxicokinetic Models Using Open-Source Descriptors</article-title>. <source>Environ. Sci. Technol.</source><volume>55</volume>, <fpage>6505</fpage>&#8211;<lpage>6517</lpage>. <comment>(plus erratum)</comment>. <pub-id pub-id-type="doi">10.1021/acs.est.0c06117</pub-id><pub-id pub-id-type="pmid">33856768</pub-id><pub-id pub-id-type="pmcid">PMC8548983</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Bruyn Kops</surname><given-names>C.</given-names></name><name name-style="western"><surname>&#352;&#237;cho</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mazzolari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kirchmair</surname><given-names>J.</given-names></name></person-group> (<year>2021</year>). <article-title>GLORYx: Prediction of the Metabolites Resulting from Phase 1 and Phase 2 Biotransformations of Xenobiotics</article-title>. <source>Chem. Res. Toxicol.</source><volume>34</volume>, <fpage>286</fpage>&#8211;<lpage>299</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrestox.0c00224</pub-id><pub-id pub-id-type="pmid">32786543</pub-id><pub-id pub-id-type="pmcid">PMC7887798</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Graaf</surname><given-names>I. A. M.</given-names></name><name name-style="western"><surname>Olinga</surname><given-names>P.</given-names></name><name name-style="western"><surname>de Jager</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Merema</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>de Kanter</surname><given-names>R.</given-names></name><name name-style="western"><surname>van de Kerkhof</surname><given-names>E. G.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Preparation and Incubation of Precision-Cut Liver and Intestinal Slices for Application in Drug Metabolism and Toxicity Studies</article-title>. <source>Nat. Protoc.</source><volume>5</volume>, <fpage>1540</fpage>&#8211;<lpage>1551</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2010.111</pub-id><pub-id pub-id-type="pmid">20725069</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Decker</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arand</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cronin</surname><given-names>A.</given-names></name></person-group> (<year>2009</year>). <article-title>Mammalian Epoxide Hydrolases in Xenobiotic Metabolism and Signalling</article-title>. <source>Arch. Toxicol.</source><volume>83</volume> (<issue>4</issue>), <fpage>297</fpage>&#8211;<lpage>318</lpage>. <pub-id pub-id-type="doi">10.1007/s00204-009-0416-0</pub-id><pub-id pub-id-type="pmid">19340413</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ekins</surname><given-names>S.</given-names></name><name name-style="western"><surname>Obach</surname><given-names>R. S.</given-names></name></person-group> (<year>2000</year>). <article-title>Three-dimensional Quantitative Structure Activity Relationship Computational Approaches for Prediction of Human <italic toggle="yes">In Vitro</italic> Intrinsic Clearance</article-title>. <source>J. Pharmacol. Exp. Ther.</source><volume>295</volume>, <fpage>463</fpage>&#8211;<lpage>473</lpage>. <pub-id pub-id-type="pmid">11046077</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elliott</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Combes</surname><given-names>R. D.</given-names></name><name name-style="western"><surname>Elcombe</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Gatehouse</surname><given-names>D. G.</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>G. G.</given-names></name><name name-style="western"><surname>Mackay</surname><given-names>J. M.</given-names></name><etal/></person-group> (<year>1992</year>). <article-title>Alternatives to Aroclor 1254-induced S9 in <italic toggle="yes">In Vitro</italic> Genotoxicity Assays</article-title>. <source>Mutagenesis</source><volume>7</volume>, <fpage>175</fpage>&#8211;<lpage>177</lpage>. <pub-id pub-id-type="doi">10.1093/mutage/7.3.175</pub-id><pub-id pub-id-type="pmid">1602970</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elsby</surname><given-names>R.</given-names></name><name name-style="western"><surname>Maggs</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Ashby</surname><given-names>J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>B. K.</given-names></name></person-group> (<year>2001</year>). <article-title>Comparison of the Modulatory Effects of Human and Rat Liver Microsomal Metabolism on the Estrogenicity of Bisphenol a: Implications for Extrapolation to Humans</article-title>. <source>J. Pharmacol. Exp. Ther.</source><volume>297</volume>, <fpage>103</fpage>&#8211;<lpage>113</lpage>. <pub-id pub-id-type="pmid">11259533</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gough</surname><given-names>A.</given-names></name><name name-style="western"><surname>Soto-Gutierrez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vernetti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ebrahimkhani</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Stern</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>D. L.</given-names></name></person-group> (<year>2021</year>). <article-title>Human Biomimetic Liver Microphysiology Systems in Drug Development and Precision Medicine</article-title>. <source>Nat. Rev. Gastroenterol. Hepatol.</source><volume>18</volume>, <fpage>252</fpage>&#8211;<lpage>268</lpage>. <pub-id pub-id-type="doi">10.1038/s41575-020-00386-1</pub-id><pub-id pub-id-type="pmid">33335282</pub-id><pub-id pub-id-type="pmcid">PMC9106093</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hariparsad</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sane</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Strom</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>Desai</surname><given-names>P. B.</given-names></name></person-group> (<year>2006</year>). <article-title>
<italic toggle="yes">In Vitro</italic> methods in Human Drug Biotransformation Research: Implications for Cancer Chemotherapy</article-title>. <source>Toxicol. Vitro</source><volume>20</volume>, <fpage>135</fpage>&#8211;<lpage>153</lpage>. <pub-id pub-id-type="doi">10.1016/j.tiv.2005.06.049</pub-id><pub-id pub-id-type="pmid">16359840</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hartman</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Beames</surname><given-names>T.</given-names></name><name name-style="western"><surname>Parks</surname><given-names>B.</given-names></name><name name-style="western"><surname>Doheny</surname><given-names>D.</given-names></name><name name-style="western"><surname>Song</surname><given-names>G.</given-names></name><name name-style="western"><surname>Efremenko</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>An <italic toggle="yes">In Vitro</italic> Approach for Prioritization and Evaluation of Chemical Effects on Glucocorticoid Receptor Mediated Adipogenesis</article-title>. <source>Toxicol. Appl. Pharmacol.</source><volume>355</volume>, <fpage>112</fpage>&#8211;<lpage>126</lpage>. <pub-id pub-id-type="doi">10.1016/j.taap.2018.05.016</pub-id><pub-id pub-id-type="pmid">29782964</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holmer</surname><given-names>M.</given-names></name><name name-style="western"><surname>de Bruyn Kops</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stork</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kirchmair</surname><given-names>J.</given-names></name></person-group> (<year>2021</year>). <article-title>CYPstrate: A Set of Machine Learning Models for the Accurate Classification of Cytochrome P450 Enzyme Substrates and Non-substrates</article-title>. <source>Molecules</source><volume>26</volume>, <fpage>4678</fpage>. <pub-id pub-id-type="doi">10.3390/molecules26154678</pub-id><pub-id pub-id-type="pmid">34361831</pub-id><pub-id pub-id-type="pmcid">PMC8347321</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuester</surname><given-names>R. K.</given-names></name><name name-style="western"><surname>Sipes</surname><given-names>I. G.</given-names></name></person-group> (<year>2007</year>). <article-title>Prediction of Metabolic Clearance of Bisphenol A (4,4 &#8242;-Dihydroxy-2,2-Diphenylpropane) Using Cryopreserved Human Hepatocytes</article-title>. <source>Drug Metab. Dispos</source><volume>35</volume>, <fpage>1910</fpage>&#8211;<lpage>1915</lpage>. <pub-id pub-id-type="doi">10.1124/dmd.107.014787</pub-id><pub-id pub-id-type="pmid">17646283</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurebayashi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Okudaira</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ohno</surname><given-names>Y.</given-names></name></person-group> (<year>2010</year>). <article-title>Species Difference of Metabolic Clearance of Bisphenol a Using Cryopreserved Hepatocytes from Rats, Monkeys and Humans</article-title>. <source>Toxicol. Lett.</source><volume>198</volume>, <fpage>210</fpage>&#8211;<lpage>215</lpage>. <pub-id pub-id-type="doi">10.1016/j.toxlet.2010.06.017</pub-id><pub-id pub-id-type="pmid">20599483</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>LeCluyse</surname><given-names>E. L.</given-names></name><name name-style="western"><surname>Witek</surname><given-names>R. P.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Powers</surname><given-names>M. J.</given-names></name></person-group> (<year>2012</year>). <article-title>Organotypic Liver Culture Models: Meeting Current Challenges in Toxicity Testing</article-title>. <source>Crit. Rev. Toxicol.</source><volume>42</volume>, <fpage>501</fpage>&#8211;<lpage>548</lpage>. <pub-id pub-id-type="doi">10.3109/10408444.2012.682115</pub-id><pub-id pub-id-type="pmid">22582993</pub-id><pub-id pub-id-type="pmcid">PMC3423873</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>P. H.</given-names></name><name name-style="western"><surname>Cucurull-Sanchez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y. J.</given-names></name></person-group> (<year>2007</year>). <article-title>Development of <italic toggle="yes">In Silico</italic> Models for Human Liver Microsomal Stability</article-title>. <source>J. Comput. Aided Mol. Des.</source><volume>21</volume>, <fpage>665</fpage>&#8211;<lpage>673</lpage>. <pub-id pub-id-type="doi">10.1007/s10822-007-9124-0</pub-id><pub-id pub-id-type="pmid">17599241</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leonard</surname><given-names>J. A.</given-names></name></person-group> (<year>2019</year>). <article-title>Supporting Systems Science through <italic toggle="yes">In Silico</italic> Applications: A Focus on Informing Metabolic Mechanisms</article-title>. <source>Curr. Opin. Toxicol.</source><volume>16</volume>, <fpage>1</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.cotox.2019.03.007</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kaminski</surname><given-names>D. L.</given-names></name></person-group> (<year>1995</year>). <article-title>Rifampicin Induction of Lidocaine Metabolism in Cultured Human Hepatocytes</article-title>. <source>J. Pharmacol. Exp. Ther.</source><volume>274</volume>, <fpage>673</fpage>&#8211;<lpage>677</lpage>. <pub-id pub-id-type="pmid">7636727</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sui</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>First-principle, Structure-Based Prediction of Hepatic Metabolic Clearance Values in Human</article-title>. <source>Eur. J. Med. Chem.</source><volume>44</volume>, <fpage>1600</fpage>&#8211;<lpage>1606</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2008.07.027</pub-id><pub-id pub-id-type="pmid">18768239</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lipinski</surname><given-names>C. A.</given-names></name></person-group> (<year>2016</year>). <article-title>Rule of Five in 2015 and beyond: Target and Ligand Structural Limitations, Ligand Chemistry Structure and Drug Discovery Project Decisions</article-title>. <source>Adv. Drug Deliv. Rev.</source><volume>101</volume>, <fpage>34</fpage>&#8211;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2016.04.029</pub-id><pub-id pub-id-type="pmid">27154268</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lipscomb</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Poet</surname><given-names>T. S.</given-names></name></person-group> (<year>2008</year>). <article-title>
<italic toggle="yes">In Vitro</italic> measurements of Metabolism for Application in Pharmacokinetic Modeling</article-title>. <source>Pharmacol. Ther.</source><volume>118</volume>, <fpage>82</fpage>&#8211;<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2008.01.006</pub-id><pub-id pub-id-type="pmid">18374419</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lombardo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Obach</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Varma</surname><given-names>M. V.</given-names></name><name name-style="western"><surname>Stringer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Berellini</surname><given-names>G.</given-names></name></person-group> (<year>2014</year>). <article-title>Clearance Mechanism Assignment and Total Clearance Prediction in Human Based upon In Silico Models</article-title>. <source>J. Med. Chem.</source><volume>57</volume>, <fpage>4397</fpage>&#8211;<lpage>4405</lpage>. <pub-id pub-id-type="doi">10.1021/jm500436v</pub-id><pub-id pub-id-type="pmid">24773013</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>B.</given-names></name><name name-style="western"><surname>Eisenhandler</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Rearden</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Manley</surname><given-names>P. J.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Prediction of Metabolic Clearance for Low-Turnover Compounds Using Plated Hepatocytes with Enzyme Activity Correction</article-title>. <source>Eur. J. Drug Metab. Pharmacokinet.</source><volume>42</volume>, <fpage>319</fpage>&#8211;<lpage>326</lpage>. <pub-id pub-id-type="doi">10.1007/s13318-016-0336-3</pub-id><pub-id pub-id-type="pmid">27101423</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mansouri</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Judson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kleinstreuer</surname><given-names>N.</given-names></name></person-group> (<year>2021</year>). <article-title>OPERA Models for ADME Properties and Toxicity Endpoints</article-title>. <source>Toxicologist, Suppl. Toxicol. Sci.</source><volume>180</volume> (<issue>S1</issue>). <comment>abstract #2543</comment>. </mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mansouri</surname><given-names>K.</given-names></name><name name-style="western"><surname>Abdelaziz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rybacka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Roncaglioni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tropsha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Varnek</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>CERAPP: Collaborative Estrogen Receptor Activity Prediction Project</article-title>. <source>Environ. Health Perspect.</source><volume>124</volume>, <fpage>1023</fpage>&#8211;<lpage>1033</lpage>. <pub-id pub-id-type="doi">10.1289/ehp.1510267</pub-id><pub-id pub-id-type="pmid">26908244</pub-id><pub-id pub-id-type="pmcid">PMC4937869</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazur</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Kenneke</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Hess-Wilson</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Lipscomb</surname><given-names>J. C.</given-names></name></person-group> (<year>2010</year>). <article-title>Differences between Human and Rat Intestinal and Hepatic Bisphenol a Glucuronidation and the Influence of Alamethicin on <italic toggle="yes">In Vitro</italic> Kinetic Measurements</article-title>. <source>Drug Metab. Dispos</source><volume>38</volume>, <fpage>2232</fpage>&#8211;<lpage>2238</lpage>. <pub-id pub-id-type="doi">10.1124/dmd.110.034819</pub-id><pub-id pub-id-type="pmid">20736320</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazzolari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Afzal</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Pedretti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Testa</surname><given-names>B.</given-names></name><name name-style="western"><surname>Vistoli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bender</surname><given-names>A.</given-names></name></person-group> (<year>2019</year>). <article-title>Prediction of UGT-Mediated Metabolism Using the Manually Curated MetaQSAR Database</article-title>. <source>ACS Med. Chem. Lett.</source><volume>10</volume> (<issue>4</issue>), <fpage>633</fpage>&#8211;<lpage>638</lpage>. <pub-id pub-id-type="doi">10.1021/acsmedchemlett.8b00603</pub-id><pub-id pub-id-type="pmid">30996809</pub-id><pub-id pub-id-type="pmcid">PMC6466832</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nussler</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Neuhaus</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>The Suitability of Hepatocyte Culture Models to Study Various Aspects of Drug Metabolism</article-title>. <source>ALTEX</source><volume>18</volume>, <fpage>91</fpage>&#8211;<lpage>101</lpage>. <pub-id pub-id-type="pmid">11378681</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ooka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Application of <italic toggle="yes">In Vitro</italic> Metabolism Activation in High-Throughput Screening</article-title>. <source>Ijms</source><volume>21</volume> (<issue>21</issue>), <fpage>8182</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21218182</pub-id><pub-id pub-id-type="pmcid">PMC7663506</pub-id><pub-id pub-id-type="pmid">33142951</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patlewicz</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wambaugh</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Felter</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>T. W.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>R. A.</given-names></name></person-group> (<year>2018</year>). <article-title>Utilizing Threshold of Toxicological Concern (TTC) with High Throughput Exposure Predictions (HTE) as a Risk-Based Prioritization Approach for Thousands of Chemicals</article-title>. <source>Comput. Toxicol.</source><volume>7</volume>, <fpage>58</fpage>&#8211;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1016/j.comtox.2018.07.002</pub-id><pub-id pub-id-type="pmid">31338483</pub-id><pub-id pub-id-type="pmcid">PMC6650166</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pelkonen</surname><given-names>O.</given-names></name><name name-style="western"><surname>Tolonen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rousu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tursas</surname><given-names>L.</given-names></name><name name-style="western"><surname>Turpeinen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hokkanen</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Comparison of Metabolic Stability and Metabolite Identification of 55 ECVAM/ICCVAM Validation Compounds between Human and Rat Liver Homogenates and Microsomes - a Preliminary Analysis</article-title>. <source>Altex</source><volume>26</volume>, <fpage>214</fpage>&#8211;<lpage>222</lpage>. <pub-id pub-id-type="doi">10.14573/altex.2009.3.214</pub-id><pub-id pub-id-type="pmid">19907907</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phillips</surname><given-names>M. B.</given-names></name><name name-style="western"><surname>Balbuena-Venancio</surname><given-names>P.</given-names></name><name name-style="western"><surname>Enders</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Norini</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Shim</surname><given-names>Y.-S.</given-names></name><name name-style="western"><surname>Burgunder</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Xenobiotic Metabolism in Alginate-Encapsulated Primary Human Hepatocytes over Long Timeframes</article-title>. <source>Appl. Vitro Toxicol.</source><volume>4</volume>, <fpage>238</fpage>&#8211;<lpage>247</lpage>. <pub-id pub-id-type="doi">10.1089/aivt.2017.0029</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pradeep</surname><given-names>P.</given-names></name><name name-style="western"><surname>Patlewicz</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pearce</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wambaugh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wetmore</surname><given-names>B.</given-names></name><name name-style="western"><surname>Judson</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>Using Chemical Structure Information to Develop Predictive Models for <italic toggle="yes">In Vitro</italic> Toxicokinetic Parameters to Inform High-Throughput Risk-Assessment</article-title>. <source>Comput. Toxicol.</source><volume>16</volume>, <fpage>10</fpage>. <pub-id pub-id-type="doi">10.1016/j.comtox.2020.100136</pub-id><pub-id pub-id-type="pmcid">PMC8193769</pub-id><pub-id pub-id-type="pmid">34124416</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Proen&#231;a</surname><given-names>S.</given-names></name><name name-style="western"><surname>Escher</surname><given-names>B. I.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>F. C.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gr&#233;goire</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hewitt</surname><given-names>N. J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Effective Exposure of Chemicals in <italic toggle="yes">In Vitro</italic> Cell Systems: A Review of Chemical Distribution Models</article-title>. <source>Toxicol. Vitro</source><volume>73</volume>, <fpage>105133</fpage>. <pub-id pub-id-type="doi">10.1016/j.tiv.2021.105133</pub-id><pub-id pub-id-type="pmid">33662518</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Punt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jeurissen</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Boersma</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Delatour</surname><given-names>T.</given-names></name><name name-style="western"><surname>Scholz</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schilter</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Evaluation of Human Interindividual Variation in Bioactivation of Estragole Using Physiologically Based Biokinetic Modeling</article-title>. <source>Toxicol. Sci.</source><volume>113</volume>, <fpage>337</fpage>&#8211;<lpage>348</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfp272</pub-id><pub-id pub-id-type="pmid">19920071</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rotroff</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Wetmore</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Dix</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Clewell</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Houck</surname><given-names>K. A.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Incorporating Human Dosimetry and Exposure into High-ThroughputIn VitroToxicity Screening</article-title>. <source>Toxicol. Sci.</source><volume>117</volume>, <fpage>348</fpage>&#8211;<lpage>358</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfq220</pub-id><pub-id pub-id-type="pmid">20639261</pub-id><pub-id pub-id-type="pmcid">PMC6280841</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarigiannis</surname><given-names>D. &#913;.</given-names></name><name name-style="western"><surname>Papadaki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kontoroupis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Karakitsios</surname><given-names>S. P.</given-names></name></person-group> (<year>2017</year>). <article-title>Development of QSARs for Parameterizing Physiology Based ToxicoKinetic Models</article-title>. <source>Food Chem. Toxicol.</source><volume>106</volume>, <fpage>114</fpage>&#8211;<lpage>124</lpage>. <pub-id pub-id-type="doi">10.1016/j.fct.2017.05.029</pub-id><pub-id pub-id-type="pmid">28522333</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sipes</surname><given-names>N. S.</given-names></name><name name-style="western"><surname>Wambaugh</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Pearce</surname><given-names>R.</given-names></name><name name-style="western"><surname>Auerbach</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Wetmore</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>J.-H.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>An Intuitive Approach for Predicting Potential Human Health Risk with the Tox21 10k Library</article-title>. <source>Environ. Sci. Technol.</source><volume>51</volume>, <fpage>10786</fpage>&#8211;<lpage>10796</lpage>. <pub-id pub-id-type="doi">10.1021/acs.est.7b00650</pub-id><pub-id pub-id-type="pmid">28809115</pub-id><pub-id pub-id-type="pmcid">PMC5657440</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Nolan</surname><given-names>C. K.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Hatfield</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>T. W.</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>S. S.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>A Comprehensive Evaluation of Metabolic Activity and Intrinsic Clearance in Suspensions and Monolayer Cultures of Cryopreserved Primary Human Hepatocytes</article-title>. <source>J. Pharm. Sci.</source><volume>101</volume>, <fpage>3989</fpage>&#8211;<lpage>4002</lpage>. <pub-id pub-id-type="doi">10.1002/jps.23262</pub-id><pub-id pub-id-type="pmid">22806329</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sobus</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Wambaugh</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Isaacs</surname><given-names>K. K.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>McEachran</surname><given-names>A. D.</given-names></name><name name-style="western"><surname>Richard</surname><given-names>A. M.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Integrating Tools for Non-targeted Analysis Research and Chemical Safety Evaluations at the Us Epa</article-title>. <source>J. Expo. Sci. Environ. Epidemiol.</source><volume>28</volume>, <fpage>411</fpage>&#8211;<lpage>426</lpage>. <pub-id pub-id-type="doi">10.1038/s41370-017-0012-y</pub-id><pub-id pub-id-type="pmid">29288256</pub-id><pub-id pub-id-type="pmcid">PMC6661898</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sweeney</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Sterner</surname><given-names>T. R.</given-names></name></person-group> (<year>2022</year>). <article-title>Prediction of Mammalian Maximal Rates of Metabolism and Michaelis Constants for Industrial and Environmental Compounds: Revisiting Four Quantitative Structure Activity Relationship (QSAR) Publications</article-title>. <source>Comput. Toxicol.</source><volume>21</volume>, <fpage>100214</fpage>. <pub-id pub-id-type="doi">10.1016/j.comtox.2022.100214</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Triggle</surname><given-names>D. J.</given-names></name></person-group> (<year>2007</year>). <source>Comprehensive Medicinal Chemistry II</source>. <publisher-loc>Amsterdam; London</publisher-loc>: <publisher-name>Elsevier</publisher-name>. </mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trdan Lu&#353;in</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ro&#353;kar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mrhar</surname><given-names>A.</given-names></name></person-group> (<year>2012</year>). <article-title>Evaluation of Bisphenol a Glucuronidation According to Ugt1a1*28 Polymorphism by a New Lc-Ms/ms Assay</article-title>. <source>Toxicology</source><volume>292</volume>, <fpage>33</fpage>&#8211;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.tox.2011.11.015</pub-id><pub-id pub-id-type="pmid">22154984</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vildhede</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wi&#347;niewski</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Nor&#233;n</surname><given-names>A.</given-names></name><name name-style="western"><surname>Karlgren</surname><given-names>M.</given-names></name><name name-style="western"><surname>Artursson</surname><given-names>P.</given-names></name></person-group> (<year>2015</year>). <article-title>Comparative Proteomic Analysis of Human Liver Tissue and Isolated Hepatocytes with a Focus on Proteins Determining Drug Exposure</article-title>. <source>J. Proteome Res.</source><volume>14</volume>, <fpage>3305</fpage>&#8211;<lpage>3314</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jproteome.5b00334</pub-id><pub-id pub-id-type="pmid">26167961</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vinci</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cavallone</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vozzi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mazzei</surname><given-names>D.</given-names></name><name name-style="western"><surname>Domenici</surname><given-names>C.</given-names></name><name name-style="western"><surname>Brunetto</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2010a</year>). <article-title>
<italic toggle="yes">In Vitro</italic> liver Model Using Microfabricated Scaffolds in a Modular Bioreactor</article-title>. <source>Biotechnol. J.</source><volume>5</volume>, <fpage>232</fpage>&#8211;<lpage>241</lpage>. <pub-id pub-id-type="doi">10.1002/biot.200900074</pub-id><pub-id pub-id-type="pmid">19824019</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vinci</surname><given-names>B.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>E.</given-names></name><name name-style="western"><surname>Iori</surname><given-names>E.</given-names></name><name name-style="western"><surname>Marescotti</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Avogaro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ahluwalia</surname><given-names>A.</given-names></name></person-group> (<year>2010b</year>). <article-title>Flow-regulated Glucose and Lipid Metabolism in Adipose Tissue, Endothelial Cell and Hepatocyte Cultures in a Modular Bioreactor</article-title>. <source>Biotechnol. J.</source><volume>5</volume>, <fpage>618</fpage>&#8211;<lpage>626</lpage>. <pub-id pub-id-type="doi">10.1002/biot.201000009</pub-id><pub-id pub-id-type="pmid">20518065</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wambaugh</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Setzer</surname><given-names>R. W.</given-names></name><name name-style="western"><surname>Reif</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Gangwal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mitchell-Blackwood</surname><given-names>J.</given-names></name><name name-style="western"><surname>Arnot</surname><given-names>J. A.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>High-throughput Models for Exposure-Based Chemical Prioritization in the Expocast Project</article-title>. <source>Environ. Sci. Technol.</source><volume>47</volume>, <fpage>8479</fpage>&#8211;<lpage>8488</lpage>. <pub-id pub-id-type="doi">10.1021/es400482g</pub-id><pub-id pub-id-type="pmid">23758710</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wambaugh</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>M. F.</given-names></name><name name-style="western"><surname>Ring</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>MacMillan</surname><given-names>D. K.</given-names></name><name name-style="western"><surname>Ford</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fennell</surname><given-names>T. R.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Evaluating In Vitro-In Vivo Extrapolation of Toxicokinetics</article-title>. <source>Toxicol. Sci.</source><volume>163</volume>, <fpage>152</fpage>&#8211;<lpage>169</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfy020</pub-id><pub-id pub-id-type="pmid">29385628</pub-id><pub-id pub-id-type="pmcid">PMC5920326</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wambaugh</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dionisio</surname><given-names>K. L.</given-names></name><name name-style="western"><surname>Frame</surname><given-names>A.</given-names></name><name name-style="western"><surname>Egeghy</surname><given-names>P.</given-names></name><name name-style="western"><surname>Judson</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>High Throughput Heuristics for Prioritizing Human Exposure to Environmental Chemicals</article-title>. <source>Environ. Sci. Technol.</source><volume>48</volume>, <fpage>12760</fpage>&#8211;<lpage>12767</lpage>. <pub-id pub-id-type="doi">10.1021/es503583j</pub-id><pub-id pub-id-type="pmid">25343693</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wetmore</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Wambaugh</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Sochaski</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Setzer</surname><given-names>R. W.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Incorporating High-Throughput Exposure Predictions with Dosimetry-AdjustedIn VitroBioactivity to Inform Chemical Toxicity Testing</article-title>. <source>Toxicol. Sci.</source><volume>148</volume>, <fpage>121</fpage>&#8211;<lpage>136</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfv171</pub-id><pub-id pub-id-type="pmid">26251325</pub-id><pub-id pub-id-type="pmcid">PMC4620046</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wetmore</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Wambaugh</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Clewell</surname><given-names>H. J.</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Judson</surname><given-names>R. S.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Relative Impact of Incorporating Pharmacokinetics on Predicting <italic toggle="yes">In Vivo</italic> hazard and Mode of Action from High-Throughput <italic toggle="yes">In Vitro</italic> Toxicity Assays</article-title>. <source>Toxicol. Sci.</source><volume>132</volume>, <fpage>327</fpage>&#8211;<lpage>346</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kft012</pub-id><pub-id pub-id-type="pmid">23358191</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilk-Zasadna</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bernasconi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pelkonen</surname><given-names>O.</given-names></name><name name-style="western"><surname>Coecke</surname><given-names>S.</given-names></name></person-group> (<year>2015</year>). <article-title>Biotransformation <italic toggle="yes">In Vitro</italic> : An Essential Consideration in the Quantitative <italic toggle="yes">In Vitro</italic> -to-<italic toggle="yes">In Vivo</italic> Extrapolation (QIVIVE) of Toxicity Data</article-title>. <source>Toxicology</source><volume>332</volume>, <fpage>8</fpage>&#8211;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/j.tox.2014.10.006</pub-id><pub-id pub-id-type="pmid">25456264</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pfeifer</surname><given-names>N. D.</given-names></name><name name-style="western"><surname>K&#246;ck</surname><given-names>K.</given-names></name><name name-style="western"><surname>Brouwer</surname><given-names>K. L. R.</given-names></name></person-group> (<year>2015</year>). <article-title>Species Differences in Hepatobiliary Disposition of Taurocholic Acid in Human and Rat sandwich-cultured Hepatocytes: Implications for Drug-Induced Liver Injury</article-title>. <source>J. Pharmacol. Exp. Ther.</source><volume>353</volume>, <fpage>415</fpage>&#8211;<lpage>423</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.114.221564</pub-id><pub-id pub-id-type="pmid">25711339</pub-id><pub-id pub-id-type="pmcid">PMC4407722</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Adeleye</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Clewell</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>P.</given-names></name><name name-style="western"><surname>Whelan</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>Moving beyond Prioritization toward True <italic toggle="yes">In Vitro</italic> Safety Assessment</article-title>. <source>Appl. Vitro Toxicol.</source><volume>2</volume> (<issue>2</issue>), <fpage>67</fpage>&#8211;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1089/aivt.2016.29005.rtl</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Clewell</surname><given-names>H. J.</given-names></name></person-group> (<year>2012</year>). <article-title>Quantitativein Vitrotoin Vivoextrapolation of Cell-Based Toxicity Assay Results</article-title>. <source>Crit. Rev. Toxicol.</source><volume>42</volume>, <fpage>633</fpage>&#8211;<lpage>652</lpage>. <pub-id pub-id-type="doi">10.3109/10408444.2012.692115</pub-id><pub-id pub-id-type="pmid">22667820</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Clewell</surname><given-names>H. J.</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Andersen</surname><given-names>M. E.</given-names></name></person-group> (<year>2013</year>). <article-title>Deriving an Explicit Hepatic Clearance Equation Accounting for Plasma Protein Binding and Hepatocellular Uptake</article-title>. <source>Toxicol. Vitro</source><volume>27</volume> (<issue>1</issue>), <fpage>11</fpage>&#8211;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/j.tiv.2012.10.003</pub-id><pub-id pub-id-type="pmid">23085432</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zamora</surname><given-names>I.</given-names></name><name name-style="western"><surname>Fontaine</surname><given-names>F.</given-names></name><name name-style="western"><surname>Serra</surname><given-names>B.</given-names></name><name name-style="western"><surname>Plasencia</surname><given-names>G.</given-names></name></person-group> (<year>2013</year>). <article-title>High-throughput, Computer Assisted, Specific Metid. A Revolution for Drug Discovery</article-title>. <source>Drug Discov. Today Tech.</source><volume>10</volume>, <fpage>e199</fpage>&#8211;<lpage>e205</lpage>. <pub-id pub-id-type="doi">10.1016/j.ddtec.2012.10.015</pub-id><pub-id pub-id-type="pmid">24050248</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>